1 / 8

Martin JSH. ECCMID 2013 abs. LB2963

1 of 2. Frequency of Clostridium difficile infection (CDI) transmission via ward contact with a known case. Retrospective, observational study (22 months; 1 laboratory providing diagnostic services for all inpatient and community care in Leeds, UK)

kedma
Download Presentation

Martin JSH. ECCMID 2013 abs. LB2963

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 1 of 2 Frequency of Clostridium difficile infection (CDI) transmission via ward contact with a known case Retrospective, observational study (22 months; 1 laboratory providing diagnostic services for all inpatient and community care in Leeds, UK) Donor-recipient matching based on common ribotype and ward contact during defined infectious periods (7 days prior and ≤56 days after donor positive test) and incubation periods (≤90 before recipient positive test) Martin JSH. ECCMID 2013 abs. LB2963 Data from poster

  2. 2 of 2 Frequency of Clostridium difficile infection (CDI) transmission via ward contact with a known case • Inpatient samples: Donor group: 75% - Recipient group: 78% Martin JSH. ECCMID 2013 abs. LB2963 Data from poster

  3. 1 of 2 Impact of new liquid oxygen releaser surface disinfectant on risk of nosocomial Clostridium difficile infection (CDI) Single-centre before-after study (2 wards of internal medicine department of university hospital; Austria): Pre-intervention phase: Conventional sporocidal surface disinfection; used only in response to occurrence of nosocomial CDI Intervention phase: New liquid oxygen releaser disinfectant; used daily, regardless of CDI occurrence Hell M. ECCMID 2013 abs. O448

  4. 2 of 2 Impact of new liquid oxygen releaser surface disinfectant on risk of nosocomial Clostridium difficile infection (CDI) Daily use of a liquid oxygen releaser disinfectant may significantly reduce the incidence of nosocomial CDI compared with conventional disinfection Hell M. ECCMID 2013 abs. O448

  5. 1 of 2 Effectiveness of donor faeces infusion for treating recurrent Clostridium difficile infection (CDI) Single-centre randomised controlled trial (2008-2010): N= 42 pts with recurrent CDI: Group 1 (N=16): Initial vancomycin (500 mg orally 4x/day for 4 days) + bowel lavage + duodenal infusion of donor faeces through nasoduodenal tube (+ 2nd infusion with donor faeces of different donor if no resolution of diarrhoea after 1st infusion) Group 2 (N=13): Standard vancomycin regimen (500 mg orally 4x/d for 14 d) Group 3 (N=13): Standard vancomycin regimen (500 mg orally 4x/d for 14 d) + bowel lavage Primary endpoint: Resolution of diarrhoea without relapse after 10 wk Study was stopped after interim efficacy analysis No sign. ≠ in baseline characteristics between treatment groups van Nood E et al. N Engl J Med 2013;368:407-15

  6. 2 of 2 Effectiveness of donor faeces infusion for treating recurrent Clostridium difficile infection (CDI) van Nood E et al. N Engl J Med 2013;368:407-15

  7. 1 of 2 Efficacy and safety of fidaxomicin vs vancomycin for Clostridium difficile infection: phase III non-inferiority trial Multi-centre, double-blind, randomised, non-inferiority trial (Europe, USA, Canada; 2007-2009) N= 535 pts with acute, toxin-positive C.difficile infection (CDI): Fidaxomicin (FDX) (N=270): 200 mg orally every 12h for 10 days Vancomycin (VCA)(N=265): 125 mg orally every 6h for 10 days 26 pts excluded; 509 pts included in modified intention-to-treat (mITT) population Safety(safety population: N=524)No significant differences in TEAEs between treatment groups Cornely OA et al. Lancet Infect Dis 2012;12:281-9 TEAE: treatment-emergent adverse event; * Possibly or definitely related to study drug

  8. 2 of 2 Efficacy and safety of fidaxomicin vs vancomycin for Clostridium difficile infection: phase III non-inferiority trial Efficacy • Primary endpoint: Clinical cure = resolution of diarrhoea and no further need for treatment • Tested hypothesis: FDX is non-inferior to VCA for primary endpoint;Criterion for non-inferiority: 1-sided lower 97.5% CI margin: -10% • Subgroup analyses of primary endpoint in mITT population: no sign. ≠Except: Fidaxomicin seems to be non-inferior to vancomycin for initial clinical response to CDI and seems to have a comparable safety profile Cornely OA et al. Lancet Infect Dis 2012;12:281-9

More Related